



ASX and Media Release

Leading US Oncologist joins Viralytics' Scientific Advisory Board

27 November 2013, Sydney, Australia: Viralytics Limited (ASX:VLA, OTCQX:VRACY) is pleased to announce the appointment of Associate Professor Keith Flaherty MD to its Scientific Advisory Board (SAB).

Dr. Flaherty is Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center and he is an Associate Professor of Medicine at Harvard Medical School.

His research and clinical focus is on melanoma with a particular expertise in targeted therapies. Dr. Flaherty has been the Principal Investigator for numerous human clinical trials with a focus on novel, targeted drugs for metastatic melanoma patients.

Dr. Flaherty has a Bachelor of Science from Yale University and a Medical Degree from Johns Hopkins University.

"I am very pleased to join the Viralytics SAB particularly given the recent positive results with CAVATAK™ in the Phase 2 CALM study. I look forward to contributing to the further development of this promising new agent," said Dr Flaherty.

Dr Malcolm McColl, Chief Executive Officer of Viralytics said: "We are delighted to welcome Dr Flaherty to our SAB. He is a recognised authority on the clinical development of new agents for melanoma including being the Principal Investigator on a Phase 3 study for a drug now approved for use in late stage melanoma patients. His specialist skills will be very valuable as we move forward in the clinic with CAVATAK™."

Enquiries:
Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company is actively enrolling a

For personal use only



phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Viralytics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and will commence the STORM trial at three prominent UK sites in late 2013.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.

For personal use only